Since 1970, Dr. David Fine, GeNO’s founder and CEO, has developed numerous nitro (-NO2) and nitroso (NO) based instrument systems, 11 of which were based on nitric oxide chemistry similar to GeNO’s nitric oxide delivery platforms. This includes the TEA analyzer for the detection of N-Nitrosamines, leak detectors for hydrazine and N2O4 liquid rocket fuels, high speed sniffing machines for Nitrogen containing organics for the beverage and bottling industry, and the development of trace explosive detectors for post blast forensic analysis and airport security.
Dr. Fine recognized that the then current thinking of delivering inhalable nitric oxide by dilution of concentrated nitric oxide was both technically unsound and fraught with difficulties, given the known non-linear kinetics of the reaction of nitric oxide with O2 to form NO2. Dr. Fine understood that knowledge of nitric oxide and NO2 chemistry was key to generating ultra pure and low cost delivery platforms for inhalation therapy.
In 2006, Dr. Fine founded GeNO, LLC to commercially develop new and innovative nitric oxide generation platforms.